Market Report Source

Overview

Introduction

Alexza was founded in 2000 as FaxMed and changed its name to Alexza Corporation in June 2001 and to Alexza Molecular Delivery Corporation in December 2001. Further, it changed its name to its present one Alexza Pharmaceuticals in July 2005.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Alexza’s clinical pipeline products include: AZ-001 (Phase II) for acute migraine headaches; AZ-002 (Phase II) for acute treatment of panic attacks associated with panic disorder; AZ-004 (Phase II) for the treatment of acute agitation in patients with schizophrenia; AZ-104 for the treatment of migraine (Phase II). Alexza currently recognizes revenues in the form of funding and milestone payments from its collaborators: Symphony Capital and Endo Pharmaceuticals. During the historical period, the company’s total revenues decreased from $2.4 million in 2004 to $1 million in 2006. The company’s biggest contributor to sales growth out to 2010 will be revenues from license fees, collaboration payments and other revenues. These revenues are expected to grow at a CAGR of more than 100%, from $1 million in 2006 to $30 million in 2010, contributing approximately 66% to Alexza’s total forecast growth.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
Landmark Products and Services
History
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Products & Services
Pipeline Products
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Discovery and Product Development
Manufacturing
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview

APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer

FIGURES
Figure 1: Alexza – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Figure 2: Alexza – Key Strategic Revenues, 2006-2010 ($ Mn)

TABLES
Table 1: Alexza – Key Facts
Table 2: Alexza – Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 3: Alexza – Key Events Impacting Share Price Performance
Table 4: Alexza – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 5: Alexza – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 6: Alexza – Balance Sheet, 2002-2006 ($ Mn)
Table 7: Alexza – Cash Flow, 2002-2006 ($ Mn)
Table 8: Alexza – In-house Pipeline Products
Table 9: Alexza – Collaboration Products
Table 10: Alexza – Forecast Sales, 2006-2010 ($ Mn)
Table 11: Alexza – Key Competitors
Table 12: Alexza – Key Clients
Table 13: Alexza – Key Shareholders
Table 14: Alexza – SWOT Analysis Summary
Table 15: Alexza – Value Chain Analysis
Table 16: Alexza – Scorecard
Table 17: Alexza – Key Employees
Table 18: Alexza – Financial and Operational Overview